Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer

IMPORTANCE: Initial approval for immune checkpoint inhibitors (ICIs) for treatment of advanced non–small cell lung cancer (NSCLC) was limited to patients with high levels of programmed cell death ligand 1 (PD-L1) expression. However, in the period after approval, it is not known how new evidence sup...

Descripción completa

Detalles Bibliográficos
Autores principales: Leapman, Michael S., Presley, Carolyn J., Zhu, Weiwei, Soulos, Pamela R., Adelson, Kerin B., Miksad, Rebecca A., Boffa, Daniel J., Gross, Cary P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280954/
https://www.ncbi.nlm.nih.gov/pubmed/32511721
http://dx.doi.org/10.1001/jamanetworkopen.2020.7205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280954/
https://www.ncbi.nlm.nih.gov/pubmed/32511721
http://dx.doi.org/10.1001/jamanetworkopen.2020.7205

Ejemplares similares